Mersana Therapeutics在1月5日更新了XMT-1536(UpRi)的临床数据。XMT-1536是靶向NaPi2b的抗体偶联药物(ADC),在1期临床的卵巢癌拓展队列中,ORR数据从去年5月公布的35%下降至28%,安全性上有31%的患者由于治疗引起的不良反应减少剂量、推迟用药或停止治疗,39%的患者发生严重不良事件,发生了1例5级肺炎。截止1月5日...
Upifitamab rilsodotin (UpRi) is a Dolaflexin, high Drug-to-Antibody Ratio ADC targeting NaPi2b, a sodium-dependent phosphate transporter broadly expressed in high-grade serous epithelial ovarian cancer, with limited expression in normal tissues. UPLIFT was a single-arm Ph2 trial evaluating the ...
XMT-1536 is a NaPi2b targeting ADC comprised of a unique humanized antibody conjugated with 10-15 auristatin F- hydroxypropylamide (AF-HPA) payload molecules via the Dolaflexin platform. AF-HPA is a cell-permeable, antimitotic compound that is slowly metabolized intratumorally to an active, very...
Upifitamab Rilsodotin(XMT-1536)是一种新型抗体-药物偶联物(ADC),由靶向NaPi2b的IgG抗体与细胞毒性药物AF-HPA通过创新型连接子偶联而成。XMT-1536能够实现肿瘤表面药物浓度的显著提升,同时其有效载荷AF-HPA具备可控的旁观者效应和有限的扩散能力,从而减少对周围健康细胞的杀伤作用。XMT-1536结合了高靶向性与低毒性...
第42课 党员干部离岗离职后违规从业、违规谋利的处分规定 党员干部离职或者退(离)休后,其原有的职权还会在
01 旗委书记张雨,旗委常委、办公室主任王勇一行实地调研明泉乳业(绿蒙)二期5000头奶牛牧场建设情况,乡党委副书记、政府乡长韩福东,乡党群服务中心副主任陈亚丽陪同。 02 旗统计局固定资产投资股股长杜云龙、干部李雅妮来明泉乳业、建华禽业指导固定资产统计上报工作。
Objectives UpRi is a first-in-class NaPi2b ADC with a novel scaffold-linker-payload that enables high drug-to-antibody ratio and controlled bystander effect. NaPi2b is a sodium-dependent phosphate transporter protein broadly expressed in high-grade serous ovarian cancer (HGSOC), with limited ...
Upifitamab Rilsodotin (UpRi) is a first-in-class Dolaflexin ADC targeting NaPi2b, a sodium-dependent phosphate transporter broadly expressed in the high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (OC), with limited expression in normal tissues. UpRi is ...
Introduction/Background UpRi is a first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that enables high drug-to-antibody ratio and controlled bystander effect. NaPi2b is a sodium-dependent phosphate transporter protein broadly expressed in high-grade serous epithelial ovarian, ...